Press release
Atopic Dermatitis Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Dermavant Sciences, Pfizer, AOBiome, Allako
Atopic Dermatitis Pipeline Insights
Atopic Dermatitis Pipeline constitutes 100+ key companies continuously working towards developing 110+ Atopic Dermatitis treatment therapies, analyzes DelveInsight.
Atopic Dermatitis Overview:
Atopic dermatitis (AD), commonly known as eczema, is a chronic inflammatory skin disorder that often starts in childhood but can affect individuals at any age. It is the most prevalent form of skin inflammation, marked by persistent itching, redness, and rashes. AD is influenced by genetic predisposition, immune system overactivity, allergies, infections, and environmental irritants. Individuals with moderate-to-severe AD often also experience other allergic conditions such as asthma, hay fever, and food sensitivities. It is particularly widespread among children, making it the most common chronic skin condition in that age group.
The onset of AD involves a complex interplay of factors, including a compromised skin barrier, immune system imbalances, IgE-related hypersensitivity, and exposure to environmental triggers. Mutations in the filaggrin gene, which is vital for skin hydration and barrier integrity, have been linked to more severe disease forms. Additionally, an immune shift from Th1 to Th2 cytokine activity and the buildup of immune cells-particularly dendritic cells-contribute to the inflammation seen in AD.
While the precise cause is still not fully understood, AD is believed to stem from a combination of genetic, immunologic, and environmental influences that impair the skin's barrier function. This results in dry, irritated, and inflamed skin that is highly sensitive to allergens and irritants. Although AD is not infectious, it can cause significant discomfort due to persistent itching and skin lesions.
Request for a detailed insights report on Atopic Dermatitis pipeline insights @ https://www.delveinsight.com/report-store/atopic-dermatitis-ad-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
"Atopic Dermatitis Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Atopic Dermatitis Therapeutics Market.
Key Takeaways from the Atopic Dermatitis Pipeline Report
*
DelveInsight's Atopic Dermatitis pipeline report depicts a robust space with 100+ active players working to develop 110+ pipeline therapies for Atopic Dermatitis treatment.
*
In April 2025, Dermavant Sciences announced that the U.S. Food and Drug Administration (FDA) has accepted the Supplemental New Drug Application (sNDA) for VTAMA as a topical treatment for atopic dermatitis.
*
Key Atopic Dermatitis companies such as Dermavant Sciences, Pfizer, AOBiome, Allakos Inc., E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd., Eli Lilly and Company, Vanda Pharmaceuticals, Suzhou Connect Biopharmaceuticals, Arcutis Biotherapeutics, Reistone Biopharma Alphyn Biologics, Argenx, Shulov Innovate for Science, Teres Bio, Qurient Co, Sun Pharmaceutical, Merck Sharp & Dohme LLC, Hangzhou Yirui Pharmaceutical Technology Co., Ltd, GI Innovation, AnaptysBio, MC2 therapeutics, Akaal Pharma, Kiniksa Pharmaceuticals, Selection, Intrinsic Medicine, Genome & Company, TWi Biotechnology, and others are evaluating new drugs for Atopic Dermatitis to improve the treatment landscape.
*
Promising Atopic Dermatitis pipeline therapies in various stages of development include Tapinarof, Etrasimod, B244, Lirentelimab, QY201: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd., and others.
Atopic Dermatitis Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Atopic Dermatitis Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Atopic Dermatitis treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Atopic Dermatitis market.
Download our free sample page report on Atopic Dermatitis pipeline insights [https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Atopic Dermatitis Emerging Drugs
*
Tapinarof: Dermavant Sciences
*
Etrasimod: Pfizer
*
B244: AOBiome
*
Lirentelimab: Allakos Inc.
*
QY201: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
Atopic Dermatitis Companies
Over 100 key companies are working on developing therapies for atopic dermatitis. Among them, Dermavant Sciences has drug candidates for atopic dermatitis in the most advanced stage, Phase III.
DelveInsight's report covers around 110+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Atopic Dermatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Atopic Dermatitis Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Atopic Dermatitis Therapies and Key Companies: Atopic Dermatitis Clinical Trials and advancements [https://www.delveinsight.com/report-store/atopic-dermatitis-ad-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Atopic Dermatitis Pipeline Therapeutic Assessment
- Atopic Dermatitis Assessment by Product Type
- Atopic Dermatitis By Stage
- Atopic Dermatitis Assessment by Route of Administration
- Atopic Dermatitis Assessment by Molecule Type
Download Atopic Dermatitis Sample report to know in detail about the Atopic Dermatitis treatment market @ Atopic Dermatitis Therapeutic Assessment [https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Atopic Dermatitis Current Treatment Patterns
4. Atopic Dermatitis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Atopic Dermatitis Late-Stage Products (Phase-III)
7. Atopic Dermatitis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Atopic Dermatitis Discontinued Products
13. Atopic Dermatitis Product Profiles
14. Atopic Dermatitis Key Companies
15. Atopic Dermatitis Key Products
16. Dormant and Discontinued Products
17. Atopic Dermatitis Unmet Needs
18. Atopic Dermatitis Future Perspectives
19. Atopic Dermatitis Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Atopic Dermatitis Pipeline Reports Offerings [https://www.delveinsight.com/report-store/atopic-dermatitis-ad-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=atopic-dermatitis-clinical-and-nonclinical-studies-key-companies-therapeutic-assessment-emerging-therapies-treatment-algorithm-and-pipeline-analysis-dermavant-sciences-pfizer-aobiome-allako]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Atopic Dermatitis Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Dermavant Sciences, Pfizer, AOBiome, Allako here
News-ID: 4090321 • Views: …
More Releases from ABNewswire
KinClub Launches New Interactive Kids Magazine, Debuting With a Holiday Issue Th …
December 11, 2025 - New York, NY - Kinovate Ventures, Inc. today announced the launch of KinClub Magazine, a dynamic new digital publication designed to engage children through a vast library of interactive pages and adaptive learning experiences. The magazine officially debuts with its first major release, the KinClub Holiday Issue [https://magazine.kin-club.com/the-holiday-season-2025], now available for free.
Key features of the KinClub Magazine experience include:
*
A Blend of Classic & Creative: The content…
Holiday Skin Stress? KREMOLOGIE Trademark Offers Professional Solutions for Sens …
Professional-grade skincare brand KREMOLOGIE addresses the seasonal skin challenges facing women this holiday season. With formulations rooted in clinical esthetics expertise, the brand provides barrier-strengthening solutions for reactive skin stressed by holiday demands, travel, and harsh winter conditions.
The holiday season brings joy, celebration, and unfortunately for many women, significant skin stress. Between November and January, dermatologists and estheticians report increased consultations for dehydration, sensitivity flare-ups, and accelerated aging signs. KREMOLOGIE…
Jupiter Landscaping Boosts Home Values in Boynton Beach With High End Landscape …
Jupiter Landscaping enhances Boynton Beach homes with luxury landscape designs, boosting curb appeal and property value.
Boynton Beach, FL - Landscaping experts in Boynton Beach are making a significant impact on home values with their top-tier landscape designs. Specializing in custom landscaping solutions, these professionals offer comprehensive services that enhance curb appeal, create functional outdoor spaces, and increase property value, especially for homeowners seeking Boynton Beach landscaping [https://www.jupiterlandscaping.net/boynton-beach-fl].
"We believe that landscaping…
Naples Comfort Systems Delivers Emergency AC Installation Solutions to Protect G …
Naples Comfort Systems provides fast emergency AC installation to keep Golden Gate families safe and cool during extreme heat.
Naples, FL - In response to the sweltering temperatures affecting Golden Gate and surrounding areas, Naples Comfort Systems is offering AC Installation Golden Gate FL [https://stahlmanac.com/air-conditioning/golden-gate-fl/] services on an emergency basis to help protect local families from the dangers of extreme heat. As the summer heat intensifies, the company is stepping up…
More Releases for Atopic
Rising Prevalence Of Atopic Dermatitis Is A Key Catalyst For The Growth Of The A …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Atopic Dermatitis Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The scope of the atopic dermatitis market has experienced substantial expansion recently, projected to increase from $8.61 billion in 2024 to reach $9.88 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 14.7%;…
Atopic Dermatitis Market Trends That Will Shape the Next Decade: Insights from P …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
How Large Will the Atopic Dermatitis Market Size By 2025?
The market size for atopic dermatitis has seen significant expansion in the past few years. This expansion is anticipated to continue, with the market size increasing from $8.61 billion in 2024 to $9.96 billion in 2025, exhibiting a compound annual growth rate (CAGR) of…
Atopic Dermatitis Pipeline Outlook Report 2024
DelveInsight's, "Atopic Dermatitis Pipeline Insight 2024" report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in the Atopic Dermatitis pipeline landscape. It covers the pipeline drug profiles, including Atopic Dermatitis clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Atopic Dermatitis Pipeline…
Advanced Therapy Revolutionizes Atopic Dermatitis Market Prospects
The atopic dermatitis market size is expected to be valued at USD 15.42 Billion in 2024 and reach USD 30.5 Billion by 2029, growing at a CAGR of 14.5 % from 2024 to 2029.
Atopic dermatitis, known as eczema, is a prevalent skin condition marked by red, inflamed, and itchy skin. It is a chronic condition commonly seen in children but can also impact adults. Atopic dermatitis is thought to result…
Atopic Dermatitis - Drug Pipeline Landscape, 2023
Atopic dermatitis (eczema) is a condition that causes dry, itchy and inflamed skin. It's characterized by inflamed skin that may crak and release a clear fluid when scratched. Eczema damages the skin barrier function that makes skin more sensitive and more prone to infection and dryness. Atopic dermatitis is caused by a combination of immune system activation, genetics, environmental triggers and stress. A weak skin barrier function might also trigger…
Atopic Dermatitis - Drug Pipeline Landscape, 2022
Atopic dermatitis (eczema) is a condition that causes dry, itchy and inflamed skin. It's characterized by inflamed skin that may cr*ck and release a clear fluid when scratched. Eczema damages the skin barrier function that makes skin more sensitive and more prone to infection and dryness.
Atopic dermatitis is caused by a combination of immune system activation, genetics, environmental triggers and stress. A weak skin barrier function might also trigger an…
